Investors Animated Over Aclaris Oral Rheumatoid Arthritis Therapy

MK2 Inhibitor Impresses In Phase IIa

Great progress has been made in the treatment of RA with biologics and JAK inhibitors but there is a space for effective small-molecule therapies and Aclaris hopes to fill it with ATI-450.

 two hands of an elderly woman sitting on a chair - Image
Aclaris looking to enter lucrative RA field • Source: Archive

Shares in Aclaris Therapeutics, Inc. have gone through the roof following the release of promising data which suggests that its experimental oral treatment for rheumatoid arthritis could shake up that highly competitive space.

The company has unveiled preliminary topline results from a Phase IIa trial of ATI-450, an oral mitogen-activated protein kinase-activated protein...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category